Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


What Goes Up … US FDA Expects 2016 NME Approval Total To Come Down

Executive Summary

After a record-setting 2015 for new drug approvals, there were not enough applications with user fee goals in 2016 to reach that level again.


Related Content

Gottlieb Q&A: Confirmation Is Nearing, Will Complete Response Letters Finally Get Released?
User Fees: Should US FDA Incur Penalties For Missed Deadlines?
Novel US FDA Approvals Could Rebound In 2017: 40+ Candidates Already Under Review
FDA's Breakthrough Workload Will Be Eased By Hiring Reviewers With PDUFA VI Funds
FDA New Drug Approval Count May Fall Back To Earth In 2016
Biosimilars Reviews Could Be Extended Two Months In BsUFA II
‘Breakthrough Therapy’ Designations
User Fee Extensions Are Key To CDER's First Cycle Review Success
Surge In Applications Triggers User Fee Inflation
First-Cycle Approval Rate Already High; Can PDUFA V Actually Boost It?





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts